Novartis (VTX:NOVN) has been given a CHF 80 price target by research analysts at Barclays in a report issued on Tuesday. The brokerage presently has a “sell” rating on the stock. Barclays’ price target points to a potential upside of 0.18% from the company’s previous close.
A number of other research firms also recently weighed in on NOVN. Berenberg Bank set a CHF 91 target price on Novartis and gave the stock a “neutral” rating in a research report on Friday, January 26th. Deutsche Bank set a CHF 90 target price on Novartis and gave the stock a “neutral” rating in a research report on Thursday, January 25th. S&P Global set a CHF 91 target price on Novartis and gave the stock a “neutral” rating in a research report on Thursday, January 25th. Morgan Stanley set a CHF 92 target price on Novartis and gave the stock a “buy” rating in a research report on Thursday, January 25th. Finally, Kepler Capital Markets set a CHF 87 target price on Novartis and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have issued a buy rating to the company’s stock. Novartis presently has an average rating of “Hold” and an average target price of CHF 88.50.
Novartis (VTX NOVN) traded up CHF 0.18 during mid-day trading on Tuesday, hitting CHF 79.86. The stock had a trading volume of 2,190,000 shares, compared to its average volume of 5,990,000. The company has a market capitalization of $209,270.00 and a P/E ratio of 26.27. Novartis has a 12 month low of CHF 72.45 and a 12 month high of CHF 88.30.
TRADEMARK VIOLATION WARNING: “Barclays Analysts Give Novartis (NOVN) a CHF 80 Price Target” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/20/barclays-analysts-give-novartis-novn-a-chf-80-price-target.html.
Novartis Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.